Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Humabiologics Receives Grant to Advance Human Collagen Biomanufacturing of Market's first Human Collagen Matrix for Regenerative Applications


News provided by

Humabologics

Jan 08, 2025, 09:05 ET

Share this article

Share toX

Share this article

Share toX

Humabiologics has been selected as one of six companies to receive a groundbreaking inaugural grant from the Piedmont Triad Regenerative Medicine Engine to help propel the Piedmont Triad region's regenerative medicine industry forward.

PHOENIX, Ariz., Jan. 8, 2025 /PRNewswire-PRWeb/ -- Humabiologics, Inc., a leading innovator in human-derived biomaterials for regenerative medicine, has been selected as one of six companies to receive a groundbreaking inaugural grant from the Piedmont Triad Regenerative Medicine Engine (PTRME). This $2.5 million total investment, funded by the National Science Foundation (NSF), will help propel the Piedmont Triad region's regenerative medicine industry forward.

Humabiologics will leverage this grant to accelerate its development of human collagen biomanufacturing of the market's first human collagen matrix for various regenerative medicine applications. Human collagen offers unique properties that hold immense potential to improve healing outcomes and enhance existing regenerative processes. More than 5.7 million Americans suffer from wounds that don't heal. Expanding biomanufacturing capabilities and regenerative medical applications of Humabiologics' technology may mean fewer people will suffer such challenges.

"We are honored to be recognized by PTRME for our work in human collagen biomanufacturing," said Dr. Mohammad Albanna, principal investigator of the grant and Founder & CEO of Humabiologics. "This grant will be instrumental in advancing our clinical translational effort, allowing us to explore the full potential of human collagen as a new class of biomaterial for regenerative medicine beyond research for clinical applications."

The PTRME, a regional driving force in translating groundbreaking research into real-world regenerative medicine solutions, is located in the Piedmont Triad region. "We are proud to see companies like Humabiologics' thrive within the PTRME ecosystem. Their efforts highlight our dedication to commercializing research, driving advancements in regenerative medicine, and fostering future manufacturing employment opportunities," said Tim Bertram, PTRME CEO.

By standardizing processes, scaling manufacturing, and prioritizing sustainability, PTRME is building a robust ecosystem where breakthrough research seamlessly translates into commercialization.

"Having worked alongside Dr. Albanna, it is inspiring to witness his commitment to advancing the field of regenerative medicine. Humabiologics' project aligns perfectly with the PTRME by driving progress and fueling the economy with the creation of new manufacturing jobs", said Dr. Anthony Atala, Chief Innovation Officer of the PTRME and Director of Wake Forest Institute of Regenerative Medicine (WFIRM).

Humabiologics will be collaborating with the Wake Forest Institute for Regenerative Medicine (WFIRM) and other members of the PTRME. The company is dedicated to pushing the boundaries of biomaterial science to develop cutting-edge solutions for regenerative medicine, contributing to the development of a thriving regenerative medicine ecosystem in the Piedmont Triad region, and ultimately translating innovation into real-world improvements in patient health and well-being.

About Humabiologics

Humabiologics is a pioneering biotechnology company dedicated to developing and producing high-quality, native human-derived biomaterials for regenerative therapies and tissue engineering applications. The company is committed to advancing the field by providing researchers with innovative and ethically sourced biomaterials that meet the highest standards. The company's products are used by researchers worldwide to drive advancements in tissue engineering, wound healing and drug discovery. Learn more at www.humabiologics.com.

About The Piedmont Triad Regenerative Medicine Engine

The Piedmont Triad Regenerative Medicine Engine (PTRME), is a National Science Foundation (NSF) funded program awarded to the Wake Forest Institute for Regenerative Medicine, supporting economic development in a 16-county region of central North Carolina through use-inspired research, technology translation, and workforce development at Wake Forest Institute for Regenerative Medicine, Winston-Salem State University, North Carolina Agricultural and Technical State University, and Forsyth Technical Community College. The Engine is a key driver of economic growth in Central North Carolina. By fostering innovation in regenerative medicine, PTRME supports the development of new technologies, creating jobs and attracting investment to the region. The initiative unites academia, industry, and government to accelerate commercialization, provide resources to startups, and train a skilled workforce, thereby cementing the Piedmont Triad as the leading hub in the rapidly growing regenerative medicine industry.

About Wake Forest Institute for Regenerative Medicine

The Wake Forest Institute for Regenerative Medicine is recognized as an international leader in translating scientific discovery into clinical therapies, with many world firsts, including the development and implantation of the first engineered organ in a patient. Over 550 people at the institute, the largest in the world, work on more than 40 different tissues and organs. A number of the basic principles of tissue engineering and regenerative medicine were first developed at the institute. WFIRM researchers have successfully engineered replacement tissues and organs in all four categories – flat structures, tubular tissues, hollow organs and solid organs – and 17 different applications of cell/tissue therapy technologies, such as skin, urethras, cartilage, bladders, muscle, kidney, and vaginal organs, have been successfully used in human patients. The institute, which is part of Wake Forest University, is located in the Innovation Quarter in downtown Winston-Salem, NC, and is driven by the urgent needs of patients. The institute is making a global difference in regenerative medicine through collaborations with over 500 entities and institutions worldwide, through its government, academic and industry partnerships, its start-up entities, and through major initiatives in breakthrough technologies, such as tissue engineering, cell therapies, diagnostics, drug discovery, biomanufacturing, nanotechnology, gene editing and 3D printing. Learn more at WFIRM.org.

Media Contact

Vish Khanna, Humabologics, 1 336-251-2560, [email protected], www.humabiologics.com

SOURCE Humabologics

Modal title

Tissue engineered blood vessel and dermal graft made from human collagen
Tissue engineered blood vessel and dermal graft made from human collagen
Tissue engineered blood vessel and dermal graft made from human collagen

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.